What is Trametinib?

Trametinib (Trametinib) is a drug used to treat certain cancers. It belongs to the category of kinase inhibitors and mainly acts on the MAPK/ERK signaling pathway. Specifically, trametinib is a MEK inhibitor that interferes with the normal function of this signaling pathway in cancer cells by inhibiting the activity of MEK kinase. This pathway plays a key role in a variety of cancers, including BRAF V600 mutation-positive malignant melanoma and non-small cell lung cancer.

By interfering with this signaling pathway, trametinib can reduce the growth, division, and spread of cancer cells, thereby inhibiting tumor progression. It is often used in combination with other chemotherapy drugs or other targeted therapies to increase efficacy. It should be noted that trametinib should only be used under the supervision of a doctor and should be taken according to the doctor's instructions. Like all medicines, trametinib may cause some side effects, such as skin reactions, tiredness, nausea, etc.

The original drug of trametinib has been launched in China and has entered the scope of Class B medical insurance, but it may only be purchased by patients who meet the indications of trametinib, such as BRAF V600 mutation-positive unresectable or metastatic melanoma. Its price is around 10,000 to 20,000 yuan. The reimbursement ratio is different in different regions, and the price is also different, making it expensive. The price of the Turkish version of the original drug Trametinib listed overseas is around RMB 7,900 (the price may fluctuate due to the exchange rate). The price of the generic version of Trametinib produced by the Lao pharmaceutical factory is around RMB 2,950 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of foreign generic drugs are basically the same as those of the domestic and foreign original drugs.